Abstract: A polysaccharide RON substance having the ultraviolet absorption spectrum depicted in FIG. 1, the infrared absorption spectrum depicted in FIG. 2 and the .sup.13 C-NMR spectrum depicted in FIG. 3 is obtained from rice bran by extraction and purification; and pharmacological composition containing said RON substance.

Abstract: Lubricating agents (spin finish) of this invention for processing synthetic yarns contain 0.05 to 10 wt % of polyalkylene oxide modified polysiloxane of a specified form an 0.5 to 8 wt % of anionic surface active agent in addition to the base of a polyether compound derived from alkylene oxide with 2 to 4 carbon atoms. Such lubricating agents exhibit superior characteristics in the production of textured yarns regarding lubricity, cohesion of yarn, anti-static capabiity and heater-deposit resistance.

Abstract: Spin finish compositions having as base oil polyether compounds which are .omega.-methoxy-poly (oxyethylene/oxypropylene) ether derivatives of a specified type and containing 0.05 to 10 weight % of polyalkylene oxide modified polysiloxane of another specified type are particularly desirable for application to polyester and polyamide yarns for ultra-high speed texturing because they have the characteristics of preventing fuzz on the yarns, thermally degraded substances and tacky white powder as well as reducing tackiness of such white powder.

Abstract: This invention is directed to a lubricant for treating synthetic fibers characterized by adding a polyethylenepolyaminepolyacetic acid derivative of the following formula (I) to a composition comprising so far known lubricating agent and surfactant, and imparts lubricating property and antistatic property to synthetic fibers in the production and processing steps thereof: ##STR1## wherein R.sub.1 and R.sub.2 is hydrogen or an alkyl or alkenyl group of 1-22 carbon atoms; n is an integer of 0-4; and M.sub.1.sup.+ -M.sub.5.sup.+ are respectively selected from the group consisting of hydrogen ion, alkali metal ion, and ammonium ion expressed e.g. by the following formula (II): ##STR2## wherein R.sub.3, R.sub.4 and R.sub.5 are respectively selected from the group consisting of hydrogen, alkyl, alkenyl, hydroxyalkyl, polyethoxyalkyl, polypropyleneoxyalkyl and polyethylenepolyaminoethyl.

Abstract: Conjugated ketone compounds of the formula: ##STR1## wherein Ar is naphthyl, furyl, thienyl, or phenyl optionally bearing one or more substituents selected from the group consisting of chlorine, bromine, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, C.sub.1 -C.sub.4 alkylthio, trifluoromethyl and methylenedioxy, R.sub.1 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.5 alkenyl, C.sub.3 -C.sub.6 cycloalkyl, C.sub.7 -C.sub.8 aralkyl or adamantyl, R.sub.2 is C.sub.1 -C.sub.6 alkyl, C.sub.3 -C.sub.5 alkenyl or C.sub.3 -C.sub.6 cycloalkyl, or when R.sub.1 and R.sub.2 are taken together with the nitrogen atom to which they are attached, they form a heterocyclic amino group containing up to 8 carbon atoms, A is straight or branched C.sub.1 -C.sub.3 alkylene, N-[4-(p-chlorophenyl)-4-oxo-2-trans-butenyl]morpholine and N-[4-(p-methoxyphenyl)-4-oxo-2-trans-butenyl]piperidine being excluded, and their non-toxic salts, which are useful as blood platelet anti-aggregative agents.

Abstract: 2(1H)-Quinazolinone and quinazolinethione derivatives having excellent pharmacological activities are produced in high yield with high purity by heating the corresponding 3,4-dihydro-2(1H)-quinazolinone or quinazolinethione derivatives together with sulfur in an inert solvent.

Abstract: Novel 9-aminoalkyl-methanoanthracenes of the formula: ##STR1## wherein A is C.sub.1 -C.sub.4 alkylene or C.sub.3 -C.sub.4 alkenylene and R.sub.1 and R.sub.2 are each hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.4 alkenyl, C.sub.3 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl(C.sub.1 -C.sub.3)alkyl, ar(C.sub.1 -C.sub.3)alkyl or polyhalo(C.sub.2 -C.sub.4)alkyl or, when taken together with the adjacent nitrogen atom, they may form a 5 to 7-membered nitrogen-containing heterocyclic ring which may contain an additional hetero atom, and their non-toxic salts, which are useful as anti-anxiety, anti-depressant, major tranquilizer, anti-histamine and anti-allergy drugs and can be prepared through a novel key intermediate, i.e. 9-formyl-9,10-dihydro-9,10-methanoanthracene, by various methods.

Abstract: A new class of 4-homoisotwistane derivatives of the formula, ##STR1## wherein R.sub.1 is a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group, and R.sub.2 is an alkyl group, a phenyl group which may be either unsubstituted or substituted with a C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy, nitro group or a halogen atom (hereinafter referred to as "an optionally substituted phenyl group"), a group of the formula, --A--OH in which A is a C.sub.1 -C.sub.3 alkylene group; a group of the formula, --A--B in which A is as defined as above and B is a halogen atom, or a group of the formula, ##STR2## in which A is as defined above and R.sub.3 and R.sub.4 are independently a hydrogen atom or a C.sub.1 -C.sub.3 alkyl group or R.sub.3 and R.sub.4 may, when taken together with the adjacent nitrogen atom to which R.sub.3 and R.sub.

Abstract: Butyrophenone compounds having excellent psychotropic activities represented by the formula: ##STR1## wherein R.sup.1 is a halogen atom, R.sup.2 is a lower alkyl group, and Z is a group of either one of the formulae: ##STR2## (wherein the dotted line indicates the optional presence of an additional single bond linkage, R.sup.3 is a hydrogen atom or a hydroxyl group but only when said additional single bond linkage is not present and R.sup.4 is a hydrogen atom or a phenyl or benzyl group optionally substituted with one or two substituents selected from the group consisting of halogen, lower alkyl, lower alkoxy and trifluoromethyl on the benzene ring (except monohalophenyl)), ##STR3## (wherein the dotted line indicates the optional presence of an additional single bond linkage, R.sup.5 is a hydrogen atom or a lower alkyl group and R.sup.6 and R.sup.7 are each a hydrogen atom, a halogen atom or a lower alkyl group), ##STR4## (wherein R.sup.8 is a hydrogen atom or a lower alkyl group and R.sup.

Abstract: There are provided compounds of the formula: ##STR1## wherein R is an adamantyl group, or a phenyl group unsubstituted or substituted with a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a halogen atom, a nitro group, a cyano group, a methylenedioxy group or an acetamido group, useful as anti-transplanted-tumor agents and immunosuppressants.

Abstract: A method for preventing gastro-intestinal ulcer caused by a non-steroidal anti-inflammatory agent, which comprises administering an effective amount of a quinazolinone of the formula, ##STR1## wherein R.sub.1 is C.sub.1-3 alkyl, cyclopropylmethyl or 2,2,2-trifluoroethyl, R.sub.2 is halogen, C.sub.1-3 alkyl or C.sub.1-3 alkoxy, and R.sub.3 is phenyl or thienyl, or a non-toxic pharmaceutically acceptable salt thereof in combination with a pharmaceutically effective amount of the non-steroidal anti-inflammatory agent.

Abstract: 2-Substituted-2'-methyl-6,7-benzomorphan derivatives of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each hydrogen or C.sub.1 -C.sub.3 alkyl; and R.sub.3 is hydrogen, halogen or C.sub.1 -C.sub.3 alkyl, and pharmaceutically acceptable salts thereof, which are useful as non-addicting analgesics with sedative effects, are prepared by the reaction of a 6,7-benzomorphan derivative of the formula: ##STR2## wherein R.sub.1 and R.sub.2 are as defined above, with a reactive derivative of an alcohol compound of the formula: ##STR3## wherein X is an optionally protected carbonyl group; and R.sub.3 is as defined above, optionally followed by the elimination of the protective group of the carbonyl group, or by the oxidation of a 6,7-benzomorphan derivative of the formula: ##STR4## wherein R.sub.1, R.sub.2 and R.sub.3 are as defined above.

Abstract: Butyrophenone compounds having excellent psychotropic activity and represented by the formula: ##STR1## wherein Z is defined hereinbelow.

Abstract: Spiro amine derivatives having excellent antihypertensive activity and central nervous system depressant activity, and represented by the formula: ##STR1## and their preparation and use.

Abstract: Antiviral agents containing an effective amount of 1-amino-2,4-ethanobicyclo[3,3,1]nonane or salts thereof which are effective for the treatment or prevention of infectious diseases caused by herpes or influenza virus.

Abstract: Novel 9-aminoalkyl-methanoanthracenes of the formula: ##STR1## wherein A is C.sub.1 -C.sub.4 alkylene or C.sub.3 -C.sub.4 alkenylene and R.sub.1 and R.sub.2 are each hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.3 -C.sub.4 alkenyl, C.sub.3 -C.sub.4 alkynyl, C.sub.3 -C.sub.6 cycloalkyl(C.sub.1 -C.sub.3)alkyl, ar(C.sub.1 -C.sub.3)alkyl or polyhalo(C.sub.2 -C.sub.4)alkyl or, when taken together with the adjacent nitrogen atom, they may form a 5 to 7-membered nitrogen-containing heterocyclic ring which may contain an additional hetero atom, and their non-toxic salts, which are useful as anti-anxiety, anti-depressant, major tranquilizer, anti-histamine and anti-allergy drugs and can be prepared through a novel key intermediate, i.e., 9-formyl-9,10-dihydro-9,10-methanoanthracene, by various methods.

Abstract: Novel benzisoxazole compounds of the formula: ##STR1## wherein R.sub.1 and R.sub.2 are each hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, ar(C.sub.1 -C.sub.3)alkoxy or halogen or, when taken together, they form C.sub.1 -C.sub.2 alkylenedioxy, Alk is C.sub.1 -C.sub.4 alkylene and A is a group of the formula: ##STR2## (wherein R.sub.3 and R.sub.4 are each C.sub.1 -C.sub.4 alkyl or, when taken together with the adjacent nitrogen atom, they represent a 5-6 membered nitrogen-containing heterocyclic ring which may contain any additional hetero atom and R.sub.5 is C.sub.1 -C.sub.4 alkyl or aryl), and non-toxic salts thereof, which possess various pharmaceutical activities.

Abstract: 3,4-Dihydro-2(1H)-quinazolinones and quniazolinethiones such as 1-cyclopropylmethyl-4-phenyl-6-methoxy-3,4-dihydro-2(1H)-quinazolinone and its thione derivative, are prepared in high yield with high purity by heating the corresponding arylurea or thiourea such as N-cyclopropylmethyl-N-(p-methoxyphenyl) urea or its thiourea derivative, with the corresponding aldehyde such as benzaldehyde in the presence of hydrobromic acid in an inert solvent.

Abstract: 1-Polyhaloalkyl-2(1H)-quinazoline derivatives of the formula, ##STR1## wherein R is polyhaloalkyl having C.sub.2 -C.sub.4 alkyl; and R.sub.1, R.sub.2 and R.sub.3 are individually hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, nitro, trifluoromethyl or halogen, have excellent anti-inflammatory and analgesic activities with very low toxicity. These quinazolinone derivatives can be prepared, for example, by reacting a trihalogenoacetamidobenzophenone derivative with ammonia.

Abstract: Tricyclic quinazolines of the formula, ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4 and A are as defined in the specification, such as 4,5-dihydro-5-arylimidazo[1,2-a]quinazolines, 4,5-dihydro-5-aryl-s-triazolo[4,3-a]quinazolines and 4,5-dihydro-5-aryltetrazolo[1,5-a]quinazolines having anti-inflammatory and analgesic activity are, for example, prepared by reducing the corresponding 4,5-unsaturated compounds, and then, if necessary, by alkylating the thus produced compounds.